-

Nomic Bio Appoints Byron Hewett to its Board of Directors

MONTREAL--(BUSINESS WIRE)--Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors. Hewett brings invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.

“We are thrilled to welcome Byron to Nomic’s board of directors as we commercialize and continue to scale our nELISA platform,” said Milad Dagher, CEO and co-founder of Nomic Bio. “Byron is a veteran in the tools space and his decades of experience and strategic insights will be instrumental during this next pivotal phase of growth.”

Mr. Hewett has more than 30 years of experience leading the development and commercialization of research and diagnostic tools. Most recently, he was CEO and Co-founder at Brava Diagnostics, focusing on point-of-care diagnostics. Previously, he was CEO of SomaLogic, a publicly listed proteomics company and Chairman and CEO of BioBehavioral Diagnostics, respectively. He was also CEO at Immunicon, and held senior roles at Qiagen, Bayer Diagnostics and Chiron Diagnostics.

“I have been following the progress of Nomic Bio for several years now and I’ve been quite impressed,” said Hewett. “Nomic's nELISA platform addresses several of the industry’s bottlenecks in a scalable and versatile manner, and I look forward to collaborating with the team as we drive the company's growth and expand its impact in the industry.”

The addition of Byron Hewett to Nomic Bio's board of directors further solidifies the company's position as a leader in the protein discovery space. Hewett will play a pivotal role in shaping the company's strategic direction and accelerating its mission to revolutionize drug development and diagnostics.

About Nomic Bio
Nomic Bio is dedicated to making proteomics as accessible as genomics. Leveraging its nELISA platform, the company aims to dramatically accelerate the discovery and development of new drugs and diagnostics. Currently, Nomic Bio offers the most comprehensive inflammatory secretome panel on the market to over 30 pharmas and biotechs, and it is continuously expanding its protein content to cover more of the proteome. Nomic Bio is headquartered in Montreal, with additional labs and offices in Boston, and it is backed by top-tier venture capital firms, including Lux Capital, SR One, and Casdin Capital.

Contacts

press@nomic.bio

Industry:

Nomic Bio

Release Summary
Nomic Bio, a company democratizing proteomics for drug discovery, announces seasoned vet Byron Hewett as a new member of its Board of Directors.
Release Versions
English
Hashtags
#proteinprofiling
#proteomics

Contacts

press@nomic.bio

Social Media Profiles
Nomic on LinkedIn
@nomicbio
More News From Nomic Bio

Nomic Publishes Foundational Protein Quantification Technology in Nature Methods

MONTREAL--(BUSINESS WIRE)--Nomic Bio (“Nomic”) today announced publication of its core nELISA® technology in Nature Methods, detailing a high‑throughput, high‑plex immunoassay platform that side-steps reagent‑driven cross‑reactivity to maintain exquisite specificity at scale. Coinciding with the publication, Nomic unveiled a 1.4 million-data-point PBMC cytokine perturbation dataset in the Nomic Portal, an intuitive platform for exploring and analyzing proteomic data. The study describes the nov...

Nomic Bio Awards Omni 1000 Proteomics Grants to Seven Institutions, Enabling 5 Million Data Points Across 5,000 Samples

MONTREAL--(BUSINESS WIRE)--Nomic Bio (“Nomic”), the Protein Profiling Company, today announced the recipients of its Omni 1000 High-Plex Proteomics Grant, a program designed to expand access to proteomics with the company’s Omni 1000 solution and Nomic platform. The grant will support seven research groups profiling more than 5,000 samples and generating over 5 million datapoints, advancing Nomic’s mission to make proteomics accessible at scale. In response to demand, Nomic more than doubled th...

Nomic Bio Debuts $50 Proteome with Absolute Quantification Through Launch of Omni 1000

MONTREAL--(BUSINESS WIRE)--Nomic Bio ("Nomic"), the Protein Profiling Company, today announced the launch of Omni 1000—a transformative high-plex solution now available through Nomic’s end-to-end service platform. Omni 1000 brings together 1,000 rigorously chosen proteins, giving scientists proteome-wide breadth while retaining coverage of hallmark targets with proven utility across drug development and translational applications. The content, designed by combining expert biomarker curation wit...
Back to Newsroom